A novel multimodal nanoplatform for targeting tumor necrosis-Reference-Cited by-同舟云学术

A novel multimodal nanoplatform for targeting tumor necrosis

Published:2021 Issue:47 Volume:11 Page:29486-29497
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Han Xiangjun¹^ORCID,Taratula Oleh²^ORCID,St Lorenz Anna²^ORCID,Moses Abraham S.²^ORCID,Albarqi Hassan A.²^ORCID,Jahangiri Younes³^ORCID,Wu Qirun¹^ORCID,Xu Ke¹^ORCID,Taratula Olena²^ORCID,Farsad Khashayar³^ORCID

Affiliation:

1. Department of Radiology, First Hospital of China Medical University, Shenyang, Liaoning, 110001, P. R. China

2. Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, USA

3. Dotter Department of Interventional Radiology, Oregon Health and Science University, Portland, Oregon 97239-3011, USA

Abstract

Au-Hyp-NP developed by encapsulation of gold and hypericin into PEG-PCL nanoplatform for fluorescence and X-ray tracking with tumor necrosis targeting.

Funder

National Natural Science Foundation of China

Oregon State University

National Institutes of Health

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/RA/D1RA05658A

Reference54 articles.

1. An overview of prognostic factors for long-term survivors of breast cancer

2. The role of cancer stem cells in the modulation of anti-tumor immune responses

3. Percutaneous stereotactic image-guided microwave ablation for malignant liver lesions

4. Effect of a hypoxic microenvironment after radiofrequency ablation on residual hepatocellular cell migration and invasion

5. Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multimodal Theranostic Nanoparticles for Necrosis Targeting, Fluorescence/SPECT Imaging, and Radiotherapy of Residual Tumors after Hepatocellular Carcinoma Ablation;Molecular Pharmaceutics;2024-03-07